文献速递耳科与耳神经头颈外科

头颈癌患者鼓膜切开或置管术后不良结局评估

Evaluating Adverse Outcomes After Myringotomy or Tube Placement in Head and Neck Cancer.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-03-19

回顾性图表综述纳入2018至2022年间因中耳积液行鼓膜切开伴或不伴置管的578例患者(736耳),其中84例(14.53%)有头颈癌病史。癌症患者持续鼓膜穿孔率更高(14.29% vs 2.43%,P<.001),总体不良事件率和复发性积液率无显著差异。作者结论认为有头颈癌或放疗史的患者鼓膜穿孔风险为三至五倍。

要点

  • 头颈癌患者鼓膜切开伴或不伴置管后持续穿孔率高于无癌症患者(14.29% vs 2.43%,P<.001)。
  • 总体不良事件率癌症组与无癌症组无显著差异(44.05% vs 44.13%,P=1.0)。
  • 复发性积液率两组无显著差异(5.95% vs 4.66%,P=.81)。

核心结论

  • 有头颈癌或放疗史的患者鼓膜切开伴或不伴置管后持续鼓膜穿孔风险为三至五倍,复发性积液率更高但无统计学意义。
  • 多变量分析显示穿孔风险为多因素性。

研究设计与样本

  • 回顾性图表综述,学术医疗中心,纳入2018年至2022年间因中耳积液行鼓膜切开伴或不伴置管的患者。
  • 共578例患者(736耳),平均随访36.6个月;癌症队列84例(14.53%)。

主要发现

  • 癌症患者平均年龄更大(62.6 vs 59.3岁,P<.05),总体不良事件率相似(44.05% vs 44.13%,P=1.0)。
  • 持续穿孔率癌症患者更高(14.29% vs 2.43%,P<.001);复发性积液率无显著差异(5.95% vs 4.66%,P=.81)。
  • 倾向评分匹配后,穿孔率差异有统计学意义(14.29% vs 1.22%,P<.01);总体不良事件率(44.05% vs 47.56%,P=.77)和复发性积液率(5.95% vs 1.22%,P=.22)无差异。

关键数值与推荐

  • 持续穿孔率:癌症组14.29% vs 非癌症组2.43%(P<.001);倾向评分匹配后癌症组14.29% vs 非癌症组1.22%(P<.01)。
  • 总体不良事件率:癌症组44.05% vs 非癌症组44.13%(P=1.0);匹配后44.05% vs 47.56%(P=.77)。
  • 复发性积液率:癌症组5.95% vs 非癌症组4.66%(P=.81);匹配后5.95% vs 1.22%(P=.22)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate rates of adverse outcomes among patients with a history of head and neck cancer undergoing myringotomy with or without tube placement for middle ear effusion. STUDY DESIGN: Retrospective chart review. SETTING: Academic medical center. METHODS: Retrospective chart review was performed on patients undergoing myringotomy with or without tube placement for middle ear effusion between 2018 and 2022. Data reviewed included demographics, cancer history, audiometry, and clinical course. RESULTS: In total, 578 patients (736 ears) had a mean follow-up of 36.6 months: 84 (14.53%) were in the cancer cohort. On average, cancer patients were older (62.6 vs 59.3 years, P < .05) but had similar rates of overall adverse outcomes (44.05% vs 44.13%, P = 1.0). Rates of persistent perforation were higher among cancer patients (14.29% vs 2.43%, P < .001); there was no significant difference in rates of recurrent effusion (5.95% vs 4.66%; P = .81). Postpropensity score matching, perforation rates reached statistical significance (14.29% vs 1.22%, P < .01). There was no difference in rate of adverse events for overall events (44.05% vs 47.56%, P = .77) or recurrent effusion (5.95% vs 1.22%, P = .22). CONCLUSION: Patients with a history of head and neck cancer or radiation have a three-to-five-fold risk of persistent tympanic membrane perforation after myringotomy with or without tube placement and a higher rate of recurrent effusion that is not significant. In multivariate analysis, perforation risk was revealed to be multifactorial.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Kuppusamy K, Yang CY, Wong K, et al. Evaluating Adverse Outcomes After Myringotomy or Tube Placement in Head and Neck Cancer. Otolaryngol Head Neck Surg. 2025. PMID: 40105435. doi:10.1002/ohn.1186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。